Skip to main
ALEC

Alector Inc (ALEC) Stock Forecast & Price Target

Alector Inc (ALEC) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 0%
Sell 25%
Strong Sell 0%

Bulls say

Alector Inc's innovative approach to neurodegenerative therapies, particularly through its advanced therapeutic candidates like AL137, AL050, and ADP064-ABC, is supported by a differentiated transferrin receptor binding technology that demonstrates significant brain uptake and favorable safety profiles. The company's focus on standardized AD biomarkers, such as pTau and amyloid PET, enhances the likelihood of achieving meaningful clinical outcomes, which could serve as positive catalysts for stock performance. Additionally, the potential for early proof-of-concept data from the ABC programs may unlock substantial shareholder value given the large addressable market within these major indications.

Bears say

Alector Inc's stock outlook has become unfavorable due to the failure of the INFRONT-3 trial of latozinemab to meet its primary endpoint, indicating significant translational biology risks that negatively impact the company's therapeutic promise. Additionally, there are substantial concerns regarding the potential failure of AL101, AL001, and AL002 to gain regulatory approval and achieve the anticipated commercial revenue, driven by limitations in market size and penetration. Furthermore, the company's valuation hinges on a discounted cash flow analysis which reflects added risks from potential negative outcomes in ongoing clinical trials and unforeseen adverse effects from its products.

Alector Inc (ALEC) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alector Inc (ALEC) Forecast

Analysts have given Alector Inc (ALEC) a Buy based on their latest research and market trends.

According to 4 analysts, Alector Inc (ALEC) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alector Inc (ALEC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.